HomeProductsBioactive CompoundsEpigeneticsEpigenetic Reader DomainMivebresib
Chemical structure of CAS 1445993-26-9

Mivebresib

CAS No.1445993-26-9
MDL No.MFCD30377200
MFC22H19F2N3O4S
MW459.50
InChI KeyRDONXGFGWSSFMY-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1445993-26-9
Product NameMivebresib

Associated Conditions

primary myelofibrosis
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.

Molecular cancer • Vol. 22, Issue 1 • 2023
PMID: 37246217PMC: PMC10226260DOI: 10.1186/s12943-023-01792-0

Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells.

PloS one • Vol. 17, Issue 4 • 2022
PMID: 35486664PMC: PMC9053788DOI: 10.1371/journal.pone.0266966

Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.

Blood cancer journal • Vol. 9, Issue 2 • 2019
PMID: 30647404PMC: PMC6333829DOI: 10.1038/s41408-018-0165-5

Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.

Journal of medicinal chemistry • Vol. 60, Issue 20 • 2017
PMID: 28949521DOI: 10.1021/acs.jmedchem.7b00746

Documentation